The World Health Organization has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting two significant developments in influenza virus evolution. The update identifies the continued spread of A (H3N2) subclade K and the growing circulation of new B/Victoria lineage strains as key factors shaping the upcoming influenza season. In response, Sino Biological has launched a comprehensive panel of antigens for these strains to accelerate influenza vaccine development worldwide.
The importance of this development lies in the specific viral threats identified by WHO for the upcoming season. Since its identification in August 2025, H3N2 subclade K has become the dominant influenza A strain globally. This strain, defined by T135K and S144N mutations, exhibits enhanced immune escape capabilities, meaning existing immunity may provide less protection against infection. This prompted WHO's selection of A/Darwin/1454/2025 as the new H3N2 reference viruses for both egg-based and cell-based vaccine production. Simultaneously, influenza B activity is rising sharply, with the proportion of B/Victoria lineage viruses increasing from 6% to over 20% in regions including Hong Kong and the United States.
Sino Biological's rapid response provides researchers with critical tools to address these evolving threats. The company has launched an extensive portfolio of recombinant antigens spanning key viral proteins including Hemagglutinin, Neuraminidase, and Nucleoprotein. For the H1N1 component, which has been updated to A/Missouri/11/2025, Sino Biological offers HA Trimer expressed in HEK293 cells with purity verified by SEC-MALS and activity validated by ELISA. The company has also made available recombinant HA, NA, and NP proteins aligned with the H3N2 subclade K reference strain A/Darwin/1454/2025. Influenza B reagents for the recommended B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025 strains are currently in development.
These high-quality research tools enable vaccine developers to work with stable HA trimers that maintain native conformation for accurate immune characterization. The availability of these antigens early in the vaccine development cycle could significantly shorten the timeline for producing effective vaccines against the strains most likely to circulate during the 2026-2027 influenza season. This matters because influenza causes significant global morbidity and mortality each year, with the elderly, young children, and those with chronic health conditions particularly vulnerable. Timely access to accurate viral antigens allows researchers to develop vaccines that better match circulating strains, potentially improving vaccine effectiveness and reducing the disease burden.
Dr. Rob Burgess, Chief Business Officer at Sino Biological US, emphasized the company's commitment to providing high-quality tools rapidly when infectious disease evolution threatens global health preparedness. The company's comprehensive antigen portfolio supports researchers in more than 90 countries working on basic research, drug discovery, and vaccine development. As influenza viruses continue to evolve through antigenic drift and shift, the availability of precisely matched research reagents becomes increasingly critical for maintaining effective vaccine protection. This development represents an important step in the annual cycle of influenza vaccine production, where early access to accurate viral materials can make a substantial difference in public health outcomes. More information about the company's products and services is available at https://www.sinobiological.com.
